|
1.
|
|
9 p, 599.8 KB |
Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia : A Study of the Acute Leukemia Working Party of the EBMT
/
Spyridonidis, Alexandros (University of Patras) ;
Labopin, Myriam (Sorbonne University) ;
Savani, Bipin (Vanderbilt University Medical Center) ;
Giebel, Sebastian (Maria Sklodowska-Curie National Research Institute of Oncology) ;
Bug, Gesine (Department of Medicine II. Goethe-University) ;
Schönland, Stefan (Medical Department V. University Hospital Heidelberg) ;
Kröger, Nicolaus (Department of Stem Cell Transplantation. University Medical Center) ;
Stelljes, Matthias (Department of Hematology/Oncology. University of Muenster) ;
Schroeder, Thomas (Department of Bone Marrow Transplantation. University Hospital) ;
Mcdonald, Andrew (Netcare Pretoria East Hospital) ;
Blau, Igor-Wolfgang (Charité - Universitätsmedizin Berlin) ;
Bornhäuser, Martin (University Hospital. TU Dresden) ;
Rovira, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bethge, Wolfgang (Department of Hematology & Oncology. University Hospital Tuebingen.) ;
Neubauer, Andreas (Philipps Universitaet Marburg) ;
Ganser, Arnold (Hannover Medical School) ;
Bourhis, Jean Henri (Gustave Roussy Cancer Campus BMT. Department of Hematology) ;
Edinger, Matthias (University Regensburg. Department of Hematology and Oncology) ;
Lioure, Bruno (Hematology. Stem Cell Transplant Unit. ICANS) ;
Wulf, Gerald (University Medicine Goettingen) ;
Schäfer-Eckart, Kerstin (Klinikum Nuernberg. 5. Medizinische Klinik. BMT-Unit) ;
Arat, Mutlu (Demiroglu Bilim Univ. Istanbul Florence Nightingale Hospital) ;
Peric, Zinaida (University Hospital Centre) ;
Schmid, Christoph (Universitatsklinikum Augsburg. Section Stem Cell Transplantation. Augsburg University and Medical Faculty) ;
Bazarbachi, Ali (Bone Marrow Transplantation Program. Department of Internal Medicine. American University of Beirut-Medical Center) ;
Ciceri, Fabio (Ospedale San Raffaele) ;
Nagler, Arnon (Hematology Division. Chaim Sheba Medical Center) ;
Mohty, Mohamad (Sorbonne Université)
In this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation (TBI) at a standard 12-Gray or at a lower 8-Gray total dose. [...]
2023 -  10.1097/HS9.0000000000000812
HemaSphere, Vol. 7 Núm. 1 (september 2023) , p. e812
|
|
|
2.
|
|
12 p, 804.5 KB |
RIC versus MAC UCBT in adults with AML : A report from Eurocord, the ALWP and the CTIWP of the EBMT
/
Baron, Frédéric (University of Liege) ;
Ruggeri, Annalisa (Hôpital Saint-Antoine (Paris, França)) ;
Beohou, Eric (Hôpital Saint-Antoine (Paris, França)) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Milpied, Noel (University of Bordeaux) ;
Michallet, Mauricette (Centre Hospitalier de Lyon Sud) ;
Bacigalupo, Andrea (Ospedale San Martino) ;
Blaise, Didier (Aix-Marseille Université) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Socié, Gérard (Hospital Saint-Louis) ;
Cornelissen, Jan J. (Erasmus Medical Center-Daniel den Hoed Cancer Center) ;
Schmid, Christoph (University of Munich) ;
Giebel, Sebastian (Gliwice Branch) ;
Gorin, Norbert-Claude (Hospital Saint Antoine) ;
Esteve, Jordi (Hematology. Hospital Clinic) ;
Ciceri, Fabio (Ospedale San Raffaele) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Mohty, Mohamad (UMRs 938) ;
Gluckman, Eliane (Centre Scientifique de Monaco) ;
Nagler, Arnon (The Chaim Sheba Medical Center) ;
Universitat Autònoma de Barcelona
Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. [...]
2016 - 10.18632/oncotarget.9599
Oncotarget, Vol. 7 Núm. 28 (2016) , p. 43027-43038
|
|
|
3.
|
|
34 p, 950.5 KB |
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
/
Pasquini, Marcelo (Medical College of Wisconsin) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Medeiros, Bruno (Stanford University School of Medicine) ;
Armand, Philippe (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hu, Zhen-Huan (Medical College of Wisconsin) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Aljurf, Mahmoud D. (King Faisal Specialist Hospital Center and Research) ;
Akpek, Görgün (Banner MD Anderson Cancer Center) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell S. (New York Medical College) ;
Cerny, Jan (UMass Memorial Medical Center) ;
Copelan, Edward A. (Carolinas HealthCare System) ;
Deol, Abhinav (Wayne State University) ;
Freytes, César O. (University of Texas Health Science Center San Antonio) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Medical Center) ;
George, Biju (Christian Medical College) ;
Gupta, Vikas (University Health Network) ;
Hale, Gregory A. (All Children's Hospital) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Klumpp, Thomas R. (Thomas Jefferson University Hospital) ;
Lazarus, Hillard M. (University Hospitals Case Medical Center) ;
Luger, Selina M. (University of Pennsylvania Medical Center) ;
Liesveld, Jane L. (University of Rochester Medical Center) ;
Litzow, Mark Robert (Mayo Clinic) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Norkin, Maxim (University of Florida College of Medicine) ;
Olsson, Richard F. (Uppsala University) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Pawarode, Attaphol (University of Michigan) ;
Pulsipher, Michael A. (University of Southern California Keck School of Medicine) ;
Ramanathan, Muthalagu (UMass Memorial Medical Center) ;
Reshef, Ran (University of Pennsylvania Medical Center) ;
Saad, Ayman A. (University of Alabama at Birmingham) ;
Saber, Wael (Medical College of Wisconsin) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Ringdén, Olle (Centre for Allogeneic Stem Cell Transplantation) ;
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center) ;
Uy, Geoffrey L. (Washington University School of Medicine) ;
Wood, William A. (University of North Carolina) ;
Wirk, Baldeep (Seattle Cancer Care Alliance) ;
Pérez, Waleska S. (Medical College of Wisconsin) ;
Batiwalla, Minoo (National Heart Lung and Blood Institute - National Institutes of Health) ;
Weisdorf, Daniel J. (University of Minnesota Medical Center) ;
Universitat Autònoma de Barcelona
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. [...]
2016 - 10.1016/j.bbmt.2015.08.024
Biology of blood and marrow transplantation, Vol. 22 Núm. 2 (january 2016) , p. 248-257
|
|
|
4.
|
|
9 p, 1.0 MB |
Improved survival after acute graft-versus-host disease diagnosis in the modern era
/
Khoury, Hanna J. (Winship Cancer Institute of Emory University) ;
Wang, Tao (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Couriel, Daniel (Utah Blood and Marrow Transplant) ;
Alousi, Amin (The University of Texas MD Anderson Cancer Center) ;
Cutler, Corey (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Battiwalla, Minoo (Lung and Blood Institute-NIH) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell (New York Medical College) ;
Chen, Yi-Bin (Massachusetts General Hospital) ;
Gale, Robert Peter (Imperial College London) ;
Hashmi, Shahrukh (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis) ;
Jagasia, Madan (Vanderbilt University Medical Center) ;
Juckett, Mark (University of Wisconsin Hospital and Clinics) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Kharfan-Dabaja, Mohamed (H. Lee Moffitt Cancer Center and Research Institute) ;
Litzow, Mark (Mayo Clinic Rochester) ;
Majhail, Navnnet (Cleveland Clinic Taussig Cancer Institute) ;
Miller, Alan (Baylor College of Medicine) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Qayed, Muna (Emory University School of Medicine) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Socie, Gerard (Hopital Saint Louis) ;
Storek, Jan (University of Calgary) ;
Verdonck, Leo (Isala Clinics Zwolle) ;
Vij, Ravi (Washington University School of Medicine) ;
Wood, Willian A. (University of North Carolina) ;
Yu, Lolie (Children's Hospital/Louisiana State University Medical Center) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Carabasi, Matthew (Thomas Jefferson University Hospital) ;
Dandoy, Christopher (Cincinnati Children's Hospital Medical Center) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ;
Hematti, Peiman (University of Wisconsin Hospital and Clinics) ;
Solh, Melham (The Blood and Marrow Transplant Group of Georgia) ;
Jamani, Kareem (University of Calgary) ;
Lehmann, Leslie (Boston Children's Hospital (Boston, Estats Units d'Amèrica)) ;
Savani, Bipin (Vanderbilt University Medical Center) ;
Schultz, Kirk R. (The University of British Columbia) ;
Wirk, Baldeep M. (Seattle Cancer Care Alliance) ;
Spellman, Stephen (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Pidala, Joseph (H. Lee Moffitt Cancer Center and Research Institute) ;
Universitat Autònoma de Barcelona
Acute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. [...]
2017 - 10.3324/haematol.2016.156356
Haematologica, Vol. 102 Núm. 5 (30 2017) , p. 958-966
|
|
|
5.
|
|
10 p, 680.7 KB |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
/
Ahmed, Sairah (University of Texas) ;
Kanakry, Jennifer A. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Ahn, Kwang Woo (Medical College of Wisconsin) ;
Litovich, Carlos Alejandro (Medical College of Wisconsin) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Aljurf, Mahmoud Deeb (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Bacher, Vera Ulrike (Inselspital. Bern University Hospital) ;
Bejanyan, Nelli (Immunotherapy. Moffitt Cancer Center) ;
Cohen, Jonathon B. (Emory University School of Medicine) ;
Farooq, Umar (University of Iowa Hospitals and Clinics) ;
Fuchs, Ephraim Joseph (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Bolaños-Meade, Javier (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Ghosh, Nilanjan S. (Levine Cancer Institute. Atrium Health) ;
Herrera, Alex F. (City of Hope National Medical Center) ;
Hossain, Nasheed (Loyola University Chicago-Stritch School of Medicine) ;
Inwards, David (Mayo Clinic) ;
Kanate, Abraham Sebastian (West Virginia University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Munshi, Pashna (Georgetown University Hospital) ;
Murthy, Hemant S. (University Florida College of Medicine) ;
Mussetti, Alberto (Institut Català d'Oncologia-Hospitalet) ;
Nieto, Yago (University of Texas) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Wirk, Baldeep Mona (Seattle Cancer Care Alliance) ;
Yared, Jean A. (University of Maryland) ;
Sureda, Anna (Institut Català d'Oncologia-Hospitalet) ;
Fenske, Timothy S. (Medical College of Wisconsin) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Universitat Autònoma de Barcelona
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. [...]
2019 - 10.1016/j.bbmt.2019.05.025
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1859-1868
|
|
|
6.
|
|
20 p, 1.9 MB |
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
/
Menghrajani, Kamal (Leukemia Service) ;
Gomez-Arteaga, Alexandra (Memorial Sloan Kettering Cancer Center) ;
Madero-Marroquin, Rafael (Icahn School of Medicine. Mount Sinai St Luke's and Mount Sinai West) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Bo-Subait, Khalid (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Sanchez, Jonathan (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Wang, Hai-Lin (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Assal, Amer (Columbia University Irving Medical Center) ;
Bacher, Vera Ulrike (Bern University Hospital) ;
Badawy, Sherif M. (Northwestern University Feinberg School of Medicine) ;
Bejanyan, Nelli (Department of Blood and Marrow Transplant and Cellular Immunotherapy. Moffitt Cancer Center) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Bredeson, Christopher (Ottawa Hospital Research Institute) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Castillo, Paul (UF Health Shands Children's Hospital) ;
Cerny, Jan (University of Massachusetts Medical Center) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Ciurea, Stefan Octavian (The University of Texas MD Anderson Cancer Center) ;
DeFilipp, Zachariah (Massachusetts General Hospital) ;
Farhadfar, Nosha (Division of Hematology/Oncology. University of Florida College of Medicine) ;
Gadalla, Shahinaz (Division of Cancer Epidemiology and Genetics. National Cancer Institute (NCI) Clinical Genetics Branch. National Institutes of Health (NIH)) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (Division of Hematological Malignancy and Cellular Therapeutics. University of Kansas Health System) ;
Gowda, Lohith (Section of Hematology. Department of Medicine. Yale University School of Medicine. Yale Comprehensive Cancer Center. Yale New Haven Hospital) ;
Grunwald, Michael R. (Department of Hematologic Oncology and Blood Disorders. Levine Cancer Institute. Atrium Health) ;
Hashmi, Shahrukh (Oncology Center. King Faisal Specialist Hospital and Research Center) ;
Hildebrandt, Gerhard (Markey Cancer Center. University of Kentucky) ;
Kanakry, Christopher G. (Experimental Transplantation and Immunology Branch. Center for Cancer Research. NCI. NIH) ;
Kansagra, Ankit (UT Southwestern Medical Center. Blood and Marrow Transplant Program) ;
Khimani, Farhad (H Lee Moffitt Cancer Center and Research Institute) ;
Krem, Maxwell (Markey Cancer Center. University of Kentucky College of Medicine) ;
Lazarus, Hillard (Department of Medicine. University Hospitals Case Medical Center. Seidman Cancer Center. Case Comprehensive Cancer Center. Case Western Reserve University) ;
Liu, Hongtao (Section of Hematology/Oncology. University of Chicago Medicine) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Michelis, Fotios V. (Allogeneic Blood and Marrow Transplant Program. Princess Margaret Cancer Centre) ;
Nathan, Sunita (Section of Bone Marrow Transplant and Cell Therapy. Rush University Medical Center) ;
Nishihori, Taiga (The Fred and Pamela Buffett Cancer Center. University of Nebraska Medical Center) ;
Olsson, Richard (Centre for Clinical Research Sormland. Uppsala University) ;
Reshef, Ran (Columbia Center for Translational Immunology. Columbia University Medical Center) ;
Rizzieri, David (Division of Hematologic Malignancies and Cellular Therapy. Duke University) ;
Rowe, Jacob M. (Department of Hematology. Shaare Zedek Medical Center) ;
Savani, Bipin N. (Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Solh, Melhem (The Blood and Marrow Transplant Group of Georgia. Northside Hospital) ;
Ustun, Celalettin (Hematology. Oncology. and Cell Therapy. Rush University Medical Center) ;
Verdonck, Leo F. (Department of Hematology and Oncology. Isala Clinic) ;
Hourigan, Christopher (National Heart Lung. and Blood Institute. NIH) ;
Sandmaier, Brenda (Clinical Research Division. Fred Hutchinson Cancer Research Center) ;
Litzow, Mark (Division of Hematology and Transplant Center. Mayo Clinic Rochester) ;
Kebriaei, Partow (Department of Stem Cell Transplantation. Division of Cancer Medicine. The University of Texas MD Anderson Cancer Center) ;
Weisdorf, Daniel (Division of Hematology. Oncology and Transplantation. Department of Medicine. University of Minnesota) ;
Zhang, Yanming (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Tallman, Martin S. (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Saber, Wael (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. [...]
2022 - 10.1182/bloodadvances.2021004881
Blood advances, Vol. 6 Núm. 3 (august 2022) , p. 828-847
|
|
|
7.
|
|
8 p, 440.5 KB |
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A Report on Behalf of the American Society for Transplantation and Cellular Therapy
/
Kharfan-Dabaja, Mohamed A. (Mayo Clinic. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program) ;
Kumar, Ambuj (Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) ;
Ayala, Ernesto (Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program. Mayo Clinic) ;
Aljurf, Mahmoud (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) ;
Nishihori, Taiga (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ;
Marsh, Rebecca (Cincinnati Children's Hospital Medical Center) ;
Burroughs, Laura M. (Fred Hutchinson Cancer Research Center) ;
Majhail, Navneet (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Al-Homsi, Ahmad Samer (NYU Langone Health) ;
Al-Kadhimi, Zaid S. (Division of Oncology and Hematology. Department of Internal Medicine. University of Nebraska Medical Center) ;
Bar, Merav (Fred Hutchinson Cancer Research Center) ;
Bertaina, Alice (Division of Stem Cell Transplant and Regenerative Medicine. Department of Pediatrics. Stanford University) ;
Boelens, Jaap Jan (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Champlin, Richard (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ;
Chaudhury, Sonali (Ann and Robert H. Lurie Children's Hospital of Chicago) ;
DeFilipp, Zachariah (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ;
El-Jawahri, Areej (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Fanning, Suzanne (Blood and Marrow Transplant Program. University of South Carolina School of Medicine) ;
Fraint, Ellen (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Gergis, Usama (Bone Marrow Transplant and Immune Cellular Therapy. Thomas Jefferson University Hospital) ;
Giralt, Sergio (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Hamilton, Betty K. (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Hashmi, Shahrukh K (Department of Medicine. Sheikh Shakhbout Medical City) ;
Horn, Biljana (Department of Pediatrics. Division of Hematology/Oncology. University of Florida. UF Health Shands Children's Hospital) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Jacobsohn, David A. (Children's National Medical Center) ;
Jain, Tania (Johns Hopkins University School of Medicine) ;
Johnston, Laura (Stanford University School of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Kansagra, Ankit (UT Southwestern Medical Center) ;
Kassim, Adetola (Vanderbilt University Medical Center) ;
Kean, Leslie S. (Boston Children's Hospital. Dana-Farber Cancer Institute) ;
Kitko, Carrie L. (Vanderbilt University Medical Center) ;
Knight-Perry, Jessica (University of Colorado School of Medicine) ;
Kurtzberg, Joanne (Duke University School of Medicine) ;
Liu, Hien (Moffitt Cancer Center) ;
MacMillan, Margaret L (University of Minnesota Medical School) ;
Mahmoudjafari, Zahra (University of Kansas Cancer Center) ;
Mielcarek, Marco (Fred Hutchinson Cancer Research Center) ;
Mohty, Mohamad (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Nemecek, Eneida (Oregon Health & Science University) ;
Olson, Timothy S. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Perales, Miguel Angel (Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Prockop, Susan E. (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Pulsipher, Michael A. (Children's Hospital Los Angeles Cancer and Blood Disease Institute. USC Keck School of Medicine) ;
Pusic, Iskra (Washington University School of Medicine) ;
Riches, Marcie L. (University of North Carolina at Chapel Hill) ;
Rodriguez, Cesar (Wake Forest University School of Medicine) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Rondon, Gabriela (The University of Texas MD Anderson Cancer Center) ;
Saad, Ayman (The Ohio State University. Division of Hematology) ;
Shah, Nina (University of California San Francisco. Department of Medicine) ;
Shaw, Peter J. (The Children's Hospital at Westmead) ;
Shenoy, Shalini (Washington University School of Medicine) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Talano, Julie (Children's Hospital of Wisconsin) ;
Verneris, Michael R. (University of Colorado School of Medicine) ;
Veys, Paul (University College London. Great Ormond Street Hospital.) ;
Wagner, John E. (University of Minnesota Medical School) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Carpenter, Paul A. (Fred Hutchinson Cancer Research Center) ;
Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. [...]
2021 - 10.1016/j.jtct.2021.04.007
Transplantation and Cellular Therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649
|
|
|
8.
|
|
13 p, 850.9 KB |
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
/
Chhabra, Saurabh (Medical College of Wisconsin) ;
Liu, Ying (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Costa, Luciano (University of Alabama at Birmingham. Department of Medicine) ;
Pidala, Joseph A. (H. Lee Moffitt Cancer Center and Research Institute) ;
Couriel, Daniel R. (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin M. (University of Texas MD Anderson Cancer Center) ;
Majhail, Navneet S. (Cleveland Clinic Taussig Cancer Institute) ;
Stuart, Robert K. (Medical University of South Carolina) ;
Kim, Dennis (Princess Margaret Cancer Center) ;
Ringden, Olle (Karolinska Institutet (Estocolm, Suècia). Division of Therapeutic Immunology) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Saad, Ayman (University of Alabama at Birmingham) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Cooper, Brenda (University Hospitals Case Medical Center. Department of Medicine-Hematology and Oncology) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Socie, Gerard (Hôpital Saint Louis. Department of Hematology) ;
Schouten, Harry C. (Academische Ziekenhuis. Department of Hematology) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Yared, Jean (University of Maryland. Greenebaum Cancer Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes. Department of Hematology) ;
Wagner, John (Thomas Jefferson University. Department of Medical Oncology) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Verdonck, Leo F. (Isala Clinic. Departmentt of Hematology/Oncology) ;
Lehmann, Leslie (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
MacMillan, Margaret L. (University of Minnesota Blood and Marrow Transplant Program) ;
Litzow, Mark R. (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Solh, Melhem M. (Northside Hospital. Blood and Marrow Transplant Group of Georgia) ;
Qayed, Muna (Emory University School of Medicine. Department of Pediatrics) ;
Hematti, Peiman (University of Wisconsin) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Vij, Ravi (Washington University School of Medicine. Division of Hematology and Oncology) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis. Division of Pediatric Hematology/Oncology) ;
Gale, Robert Peter (Imperial College London. Hematology Research Centre) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Seo, Sachiko (National Cancer Research Center East) ;
Hashmi, Shahrukh K (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Teshima, Takanori (Kyushu University Hospital) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center. Department of Medical Oncology) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Spellman, Stephen R. (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. [...]
2019 - 10.1016/j.bbmt.2018.08.018
Biology of blood and marrow transplantation, Vol. 25 Núm. 1 (january 2019) , p. 73-85
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
